pd-l1 t-hank
Cell therapyexperimental
Clinical trial activity
7 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Jul 18, 2019 (NCT04050709)
Timeline
Indications
Mechanism of action
- Tumor antigensImmunity, passive
immunity, passive - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06061809 | Phase 2 | Feb 29, 2024 | ImmunityBio, Inc. |
| NCT06239220 | Phase 2 | Feb 16, 2024 | Harvard University, ImmunityBio, Inc. |
| NCT06161545 | Phase 2 | Jan 3, 2024 | National Cancer Institute (NCI) |
| NCT04847466 | Phase 2 | Dec 7, 2021 | National Cancer Institute (NCI) |
| NCT04927884 | Phase 1/Phase 2 (Phase 2) | Sep 27, 2021 | ImmunityBio, Inc. |
| NCT04390399 | Phase 2 | May 11, 2020 | ImmunityBio, Inc. |
| NCT04050709 | Phase 1 | Jul 18, 2019 | NantWorks |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ImmunityBio, Inc. | For profit | 4 | 3 | 1 | 2020 |
| National Cancer Institute (NCI) | Government | 2 | 2 | 1 | 2021 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| NantWorks | For profit | 1 | 1 | 1 | 2019 |
4 organizations
Page 1 / 1